AccuNeb is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). It is the only lower-concentration, unit-dose albuterol approved for treating patients.

Ensure Efficacy and Reduce the Risk of Side Effects

• Multi-dose albuterol offered economy at the risk of errors, cross-contamination, BAC allergy, and respiratory infection.
• Unit-dose, full-strength albuterol offered the convenience of unit-dosing at the risk of unnecessary side effects.

Convenient, Cost-Effective, Clinically Proven

• Accurate Dosing for Ages 2 to 12
  
  • Unit-dose vial ensures fast, precise dosing.
  • Lower dosage follows NAEPP dosing guidelines for pediatric asthma patients.
  • The Result: Less time spent preparing and administering medication as well as training patients and their parents.
  
  
• Premixed, Premeasured
  
  • Easy-to-open, tamper-evident TwistFlex™ vials help reduce mixing errors and cross-contamination.
  • AccuNeb is sterile, and free of preservatives and BAC. No refrigeration is necessary.
  • The Result: Greater patient compliance for better disease management.
  
  
• Safe and Effective
  
  • AccuNeb demonstrates significant improvement in FEV₁ compared to placebo.
  • A favorable side-effects profile indicates less than 1% incidence of beta₂-agonist-related adverse effects.
  • The Result: Proven efficacy with reduced incidence of medication waste or dosing errors.

AccuNeb is available in two strengths: 0.63 mg (expressed as albuterol, equivalent to 0.75 mg albuterol sulfate) and 1.25 mg (equivalent to 1.5 mg albuterol sulfate).

Cautions: Like other beta-adrenergic agonists, AccuNeb can produce paradoxical bronchospasm, which may be life-threatening. AccuNeb should be used with caution in patients with cardiovascular disorders and patients being treated with epinephrine, oral sympathomimetics, beta-blockers, monoamine oxidase inhibitors, or tricyclic antidepressants.